SUNNY

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
  The FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claims
  stat · 8d ago
• Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter
  July 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of…
  fda_recalls · 13d ago
• STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
  A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
  stat · 13d ago
• STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
  Novo Nordisk sued Eli Lilly for allegedly running “deceptive” ads to make its obesity and diabetes drugs appear more effective
  stat · 15d ago
• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
  After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
  fiercebiotech · 19d ago
• Opinion: MAHA is rewriting the vocabulary of American mental health care
  “‘Deprescribing’ elevated into a movement, and a cultural default, is a clinical hazard,” writes Sunny Patel.
  stat · 20d ago
• STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
  More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
  stat · 1mo ago
• STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
  The 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge
  stat · 2mo ago
• STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
  Sanofi asked the FDA to pull teplizumab out of a speedy review voucher program after a political appointee disagreed with staff over its approval
  stat · 3mo ago
• STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
  HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
  stat · 3mo ago